Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Kirin Brewery Wins Epoetin Patent Suit Against Snow Brand Milk
February 12, 2001
- Typographical Error Found in NHI Price of Lorcam Presented to Chuikyo
February 12, 2001
- JMA, Kemporen Leaders Agree on Need to Exchange Opinions in April
February 5, 2001
- OTC NEWS IN BRIES
February 5, 2001
- REGULATORY NEWS IN BRIEF
February 5, 2001
- GE-Yokogawa Medical Systems Focuses on Cardiovascular Devices
February 5, 2001
- More Than 80% of Clinics Selected Fixed Sum Copayment: PJ Survey
February 5, 2001
- Boston Scientific Japan: New Balloon Catheters for PTCA
February 5, 2001
- 80.7% of Clinics Select Fixed Sum Copayment
February 5, 2001
- MEDICAL DEVICE NEWS IN BRIEF
February 5, 2001
- Takeda to Carry Out Reform with Global Standard: President Takeda
February 5, 2001
- 50% of Outpatients Should Pay Fixed Rate Copayment Overall: HIB
February 5, 2001
- WORLD NEWS IN BRIEF
February 5, 2001
- Korosho Holds 1st Explanatory Meeting for Prefectural Governmental Officials -2-
February 5, 2001
- JPA Holds National Convention to Prevent Dispensing Errors
February 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
February 5, 2001
- BUSINESS NEWS IN BRIEF
February 5, 2001
- Cost Curtailment Policy Should Now Target Hospitalization: JHEF Seminar
February 5, 2001
- Takara Obtains Marketing Rights for Analysis Services from GeneFormatics
February 5, 2001
- ON THE MOVE
February 5, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…